10-Q/A: Cannabis Bioscience International Holdings Files Amended Quarterly Report After Immaterial Errors

Cannabis Bioscience International Holdings has filed an amended 10-Q report to correct minor errors in its financial discussion, while the core financials remain unchanged.

Summary

• Cannabis Bioscience International Holdings filed an amendment to its quarterly report on Form 10-Q for the period ended August 31, 2024.
• The amendment was made to correct immaterial errors in the Management's Discussion and Analysis section, specifically regarding net loss and changes in financial condition.
• The original filing was made on August 21, 2024, and this amendment was filed on October 31, 2024.
• The company's net loss for the quarter ended August 31, 2024, was $76,305, compared to a net loss of $181,789 for the same quarter in 2023.
• If a non-cash expense of $100,000 had not been incurred, the company would have recorded a net income of $26,305 for the quarter.
• As of August 31, 2024, the company had $969 in cash and cash equivalents, $17,176 in accounts receivable, and negative working capital of $833,355.
• The company had a negative cash balance of $579 on the date of the report.
• The financial statements themselves were not changed by this amendment and were reviewed by the company's registered public accounting firm.

Sentiment

Score: 5

Explanation: The document shows a mixed picture with improved net loss but concerning cash levels and negative working capital. The amendment is for minor corrections, not a major restatement.

Positives

• The company's net loss decreased significantly from $181,789 in Q3 2023 to $76,305 in Q3 2024.
• The company would have been profitable with a net income of $26,305 if not for a $100,000 non-cash expense.

Negatives

• The company has a very low cash balance of $969 as of August 31, 2024, and a negative cash balance of $579 on the date of the report.
• The company has negative working capital of $833,355 as of August 31, 2024.

Risks

• The company's low cash balance and negative working capital could pose a risk to its operations.
• The company's reliance on non-cash expenses impacting profitability could be a concern.

Management Comments

• Dante Picazo, Principal Executive Officer and Principal Accounting Officer, certified the accuracy of the report.

Industry Context

The cannabis industry is highly competitive and subject to regulatory changes, making financial stability crucial for companies like Cannabis Bioscience International Holdings.

Comparison to Industry Standards

• It is difficult to compare the results directly to industry standards without more specific information on the company's operations and the broader cannabis market.
• Many cannabis companies are still in the growth phase and may have negative working capital and low cash balances.
• The company's significant reduction in net loss year-over-year is a positive sign, but the low cash balance and negative working capital are concerning.

Stakeholder Impact

• Shareholders may be concerned about the low cash balance and negative working capital.
• Employees may be concerned about the company's financial stability.

Key Dates

Keywords

Cannabis Bioscience International Holdings, 10-Q/A, amended quarterly report, net loss, financial condition, working capital, cash balance, non-cash expense